JP2015511226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511226A5 JP2015511226A5 JP2014554975A JP2014554975A JP2015511226A5 JP 2015511226 A5 JP2015511226 A5 JP 2015511226A5 JP 2014554975 A JP2014554975 A JP 2014554975A JP 2014554975 A JP2014554975 A JP 2014554975A JP 2015511226 A5 JP2015511226 A5 JP 2015511226A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- sample
- level
- patient
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593249P | 2012-01-31 | 2012-01-31 | |
| US61/593,249 | 2012-01-31 | ||
| PCT/US2013/023921 WO2013116385A1 (en) | 2012-01-31 | 2013-01-30 | Predictive biomarker for hypoxia-activated prodrug therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214327A Division JP2018052956A (ja) | 2012-01-31 | 2017-11-07 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015511226A JP2015511226A (ja) | 2015-04-16 |
| JP2015511226A5 true JP2015511226A5 (enExample) | 2016-03-17 |
Family
ID=48905801
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014554975A Pending JP2015511226A (ja) | 2012-01-31 | 2013-01-30 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
| JP2017214327A Withdrawn JP2018052956A (ja) | 2012-01-31 | 2017-11-07 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017214327A Withdrawn JP2018052956A (ja) | 2012-01-31 | 2017-11-07 | 低酸素活性化プロドラッグ療法のための予測バイオマーカー |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20150005264A1 (enExample) |
| EP (1) | EP2810076A4 (enExample) |
| JP (2) | JP2015511226A (enExample) |
| WO (1) | WO2013116385A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1896040T1 (sl) | 2005-06-29 | 2012-12-31 | Threshold Pharmaceuticals, Inc. | Fosforamidatna alkilatorska predzdravila |
| JP2015500885A (ja) | 2011-12-22 | 2015-01-08 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | 癌を治療するためのｃｈｋ１阻害剤と組み合わせた低酸素活性化プロドラッグの投与 |
| WO2015025283A2 (en) * | 2013-08-20 | 2015-02-26 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Dual action carbonic anhydrase inhibitors |
| US10071109B2 (en) | 2013-11-06 | 2018-09-11 | Molecular Templates, Inc. | Predictive biomarker for hypoxia-activated prodrug therapy |
| WO2016081547A1 (en) * | 2014-11-19 | 2016-05-26 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
| EP4549467A3 (en) * | 2016-08-01 | 2025-07-23 | ImmunoGenesis, Inc. | Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer |
| CN118076359A (zh) | 2021-08-27 | 2024-05-24 | 深圳艾欣达伟医药科技有限公司 | 使用th-302治疗parp抑制剂耐药的患者 |
| CN117651548A (zh) | 2021-08-27 | 2024-03-05 | 深圳艾欣达伟医药科技有限公司 | 冻干制剂溶液及冻干制剂、方法和用途 |
| US20250186468A1 (en) | 2022-03-15 | 2025-06-12 | Ascentawits Pharmaceuticals, Ltd. | Method for treating patient with brca-mutated cancer |
| CN119384281A (zh) | 2022-04-15 | 2025-01-28 | 深圳艾欣达伟医药科技有限公司 | 使用th-302单药或联用parp抑制剂治疗癌症的方法 |
| WO2023226959A1 (zh) | 2022-05-23 | 2023-11-30 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| CN119894521A (zh) | 2022-09-22 | 2025-04-25 | 深圳艾欣达伟医药科技有限公司 | 乏氧激活的化合物在制备治疗癌症患者的药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE026218T2 (en) * | 2002-02-21 | 2016-05-30 | Inst Virology | MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice |
| EP1743038A4 (en) * | 2004-05-04 | 2007-11-21 | Bayer Healthcare | MN / CA IX / CA9 AND KIDNEY CANCER PROGNOSIS |
| KR20130045341A (ko) * | 2010-07-12 | 2013-05-03 | 쓰레솔드 파마슈티컬스, 인코포레이티드 | 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여 |
-
2013
- 2013-01-30 JP JP2014554975A patent/JP2015511226A/ja active Pending
- 2013-01-30 WO PCT/US2013/023921 patent/WO2013116385A1/en not_active Ceased
- 2013-01-30 EP EP13744373.5A patent/EP2810076A4/en not_active Withdrawn
- 2013-01-30 US US14/375,417 patent/US20150005264A1/en not_active Abandoned
-
2017
- 2017-11-07 JP JP2017214327A patent/JP2018052956A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511226A5 (enExample) | ||
| Paez‐Ribes et al. | Targeting senescent cells in translational medicine | |
| Saad et al. | ADAM 17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer | |
| Wu et al. | IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms | |
| Li et al. | Uncontrolled inflammation induced by AEG-1 promotes gastric cancer and poor prognosis | |
| Chen et al. | Angiopoietin‐like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma | |
| Dai et al. | Characterization of the oncogenic function of centromere protein F in hepatocellular carcinoma | |
| JP2016513640A5 (enExample) | ||
| Pai Bellare et al. | Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition | |
| Jiao et al. | Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax | |
| JP2018503618A5 (enExample) | ||
| BR112015026095A8 (pt) | método de utilizar biomarcadores responsivos ao tumor, método para seleção de pelo menos uma droga antitumoral, composição compreendendo uma droga antitumoral, combinação para controlar a dosagem de uma droga antitumoral, uso dos biomarcadores responsivos ao tumor | |
| UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
| TR201909355T4 (tr) | Oral uygulama için proton bağlayıcı polimerler. | |
| Ying et al. | IL-17A contributes to skeletal muscle atrophy in lung cancer-induced cachexia via JAK2/STAT3 pathway | |
| Zhu et al. | REGγ drives Lgr5+ stem cells to potentiate radiation induced intestinal regeneration | |
| DOP2011000282A (es) | Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| JP2019537619A5 (enExample) | ||
| Miller et al. | Differential involvement of gp130 signalling pathways in modulating tobacco carcinogen-induced lung tumourigenesis | |
| Lv et al. | Neuropeptide Y1 receptor inhibits cell growth through inactivating mitogen-activated protein kinase signal pathway in human hepatocellular carcinoma | |
| Cañadas et al. | Angiopoietin-2 is a negative prognostic marker in small cell lung cancer | |
| JP2018537519A5 (enExample) | ||
| Jin et al. | Widdrol, a sesquiterpene isolated from Juniperus chinensis, inhibits angiogenesis by targeting vascular endothelial growth factor receptor 2 signaling | |
| Li et al. | Silibinin inhibits migration and invasion of the rhabdoid tumor G401 cell line via inactivation of the PI3K/Akt signaling pathway |